Successful treatment of cystoid macular edema with valdecoxib.
To evaluate the safety and efficacy of the COX-2 inhibitor valdecoxib in treating macular edema after cataract surgery. University Eye Clinic, Freiburg, Germany and Reis Medical Institution, Liechtenstein. The COX-2 inhibitor valdecoxib (Bextra) was administered systemically to patients with significant visual loss resulting from macular edema in a prospective clinical trial. Ten patients were enrolled. Valdecoxib was tolerated well and led to a significant visual improvement within 10 days of therapy in all patients. The fast and persistent control of macular edema with valdecoxib warrants further investigation.